Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)
Opportunity Category Explanation:
Funding Instrument Type:
Category of Funding Activity:
Food and Nutrition Health
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Department of Health and Human Services National Institutes of Health
Jan 06, 2021
Oct 15, 2021
Last Updated Date:
Jan 06, 2021
Estimated Total Program Funding:
Expected Number of Awards:
The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.